Overview of the CONFORM™ PlatformThe CONFORM™ platform by EDETEK offers a multifaceted approach to managing clinical data, focusing on five…
Browsing: General
Presented by Dr. Hedyeh Ebrahimi, City of HopeOverview: At the ASCO 2024 conference, Dr. Hedyeh Ebrahimi of City of Hope…
IntroductionDuring the CAR-T & Bispecifics Conference, Dr. Brian Sworder, MD, from UCI Irvine, shared compelling insights on the utility of…
…The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing a…
Preventing a Carboplatin Shortage: Strategies to Ensure Cancer Drug Availability in 2023 In an era where advancements in cancer treatment…
In a discussion with Allen Wilbanks from Oncology Tube, Brandon McNaughton, CEO & Founder of Akadeum Life Sciences, shed light…
OneOncology, a rapidly expanding national platform for independent medical practices, proudly announces the completion of 25 distinctive oncology and hematology…
The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential…
Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine…
Presented By: Brian Warnecke, DO – UC-Irvine Hematology Oncology Fellow, PGY-5 Date: August 12, 2023The presentation titled “Multi-omic Characterization of…
Clinical trials, as many are aware, often face numerous failures. Countless molecules are tested before finding a successful one. Anju,…
The Impact of ASCO 2022 on Oncology In the ever-evolving field of oncology, ASCO 2022 stands out as a landmark…
Laure-Anne Teuwen, MD, PhD from Antwerp University Hospital, and Joanna Young, DO, FACP from Blue Ridge Cancer Care examined the…
ASCO 2023 Press Briefing June 6, 2024 with Julie Gralow, MD ASCO Chief Medical Officer
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…
For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
El Dr. Eric Singh, uno de los participantes en el Programa de Embajadores de Educación para Pacientes GRACE del año…
Dr. Eric Singh, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video…
John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he…
John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he…
Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he…
Dr. Shikha Jain of the University of Illinois & Chair of the Women in Medicine Summit joins Charu Aggarwal &…
Professor Yves Chabu, Ph.D. from MU College of Arts and Science speaks about Understanding How Cancer Can Relapse.Link to Abstract:https://showme.missouri.edu/2021/understanding-how-cancer-can-relapse/Activating…
David Illson, MD, Ph.D., Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College.@ILSONDavid @sloan_kettering…
Dr. Matthew Katz, radiation oncologist in Lowell, MA, speaks with Drs. Jack West & Charu Aggarwal about the evolution of…
Dr. Larry Shulman of University of Pennsylvania meets with hosts Charu Aggarwal & Jack West to discuss the promise &…
Hosts Jack West and Charu Aggarwal meet with Dr. Vince Miller to discuss the process of deciding to move from…
David Illson, MD, Ph.D., Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College.@ILSONDavid @sloan_kettering…
Professor Yves Chabu, Ph.D. from MU College of Arts and Science speaks about Understanding How Cancer Can Relapse.Link to Abstract:https://showme.missouri.edu/2021/understanding-how-cancer-can-relapse/Activating…
Dr. Steve Vogl of “Vogl, New York” fame joins hosts Charu Aggarwal and Jack West as they discuss the priorities…
Drs. Aggarwal & West welcome Drs. Jerad Gardner from Geisenger Medical Labs & Sanjay Mukhopadyay from Cleveland Clinic as they…
Johannes A. Schmid, Ph.D. from MedUni Vienna speaks about How inflammatory signaling molecules contribute to carcinogenesis.Link to Article -https://www.sciencedaily.com/releases/2021/02/210217114327.htmThe Whole…
Co-hosts Charu Aggarwal and Jack West are joined by Dr. Toni Choueiri to discuss the role of twitter for education,…
Co-hosts Charu Aggarwal and Jack West are joined by Dr. Don Dizon to discuss the role social media plays in…
Drs. West and Aggarwal host Dr. Nora Disis of Univ of Washington, Editor-in-Chief of JAMA Oncology as they discuss how…
Martin Dietrich, MD from Florida Cancer Specialists speaks about the FDA Approves FoundationOne®CDx as Companion Diagnostic for Vitrakvi® (larotrectinib), to…
Co-hosts Charu Aggarwal and Jack West are joined by Dr. Jamie Von Roenn and Christopher Merlan to discuss the landscape…
In this edition of The Onco’Zine Brief Peter Hofland talks with Peter Keeling about Personalized Medicine, diagnostic testing, and the…
In this episode of The Onco’Zine Brief Peter Hofland Ph.D., talks with Raj Malik M.D. and Robert Epstein M.D.Malik is…
Pablo Okhuysen, MD, FACP, FIDSA of MD Anderson discusses the Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical…
Drs. Charu Aggarwal and Jack West chat with Dr. Gil Morgan, Medical Oncologist at SkÃ¥ne University Hospital in Lund, Sweden…
Filip Janku, MD of MD Anderson discusses Next generation BRAF inhibitor cancer drug shows promise in early patient trial.In an…
Ruben Mesa, MD, Director Mays Cancer Center, UT Health San Antonio, MD Anderson Cancer Center discusses The Future Directions in…
Udai Banerji, MD, MBBS, DNB, Ph.D., FRCP from The Institute of Cancer Research and The Royal Marsden and Jon Pachter,…
Philadelphia, PA (October 28, 2020) – Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human…
Ramaprasad Srinivasan, M.D., Ph.D. of the NIH National Cancer Institute speaks about the ESMO 2020 abstract Phase II study of…
Marcia S. Brose, MD, Ph.D. of the Pearlman School of Medicine at The University of Pennsylvania speaks on the ESMO…
Marcia S. Brose, MD, Ph.D. of the Pearlman School of Medicine at The University of Pennsylvania discusses the ESMO 2020…
Ian Chau, MD from Royal Marsden Hospital speaks about the ESMO 2020 abstract Initial safety and efficacy findings with bavituximab…
Ian Chau, MD from Royal Marsden Hospital discusses the ASCO abstract Initial safety run-in findings with bavituximab plus pembrolizumab in…
Timothy A. Yap, MD of MD Anderson discusses ESMO 2020 Poster: Rucaparib + Sacituzumab Govitecan: Initial Data From the Phase…
Dr. Zeynep Zengin, post-doctoral fellow at City of Hope discusses the ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor…
Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland discusses ESMO – Survival benefits of larotrectinib in…
Peter R. Galle, MD of University Medical Center Mainz discusses his ESMO 2020 abstract – Updated results of a phase…
Jacob J. Adashek, DO of the Moffitt Cancer Center explains the ESMO 2020 Abstract – Personalized molecularly matched therapies for…
Lillian Siu, MD of the Princess Margaret Cancer Centre discusses ESMO 2020 abstract #524O, Proffered Paper: Initial Results of a…
Eric Jonasch, MD The University of Texas MD Anderson Cancer Center ASCO 2020 Phase II study of the oral HIF-2α…
S. Michelle Shiller, DO, AP/CP, MGP at PathGroup discusses how the Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use…
Nick Smith-Stanley, MBA, Associate Director of Administration & Strategic Planning of the LIVESTRONG Cancer Institutes, Dell Medical School speaks about…
Greg Hiebert, Leadership Educator, Coach, and Consultant of Leadership Forward discusses Leadership Resilience and Post Traumatic Growth & Live. Great…
David R. Gandara, MD at MDAnderson discusses Guardant Health’s FDA approval of the Guardant360 CDx which delivers critical genomic information…
Aurélien Marabelle, MD at Gustave Roussy discusses the FDA Approval of Second Biomarker-Based Indication for Pembrolizumab (KEYTRUDA) The FDA issued…
Wendy Stock, MD of University of Chicago receives 2020 Mentor Award Recipient The Anjuli Seth Nayak Professor of Leukemia at…
Timothy A. Yap, MD from MD Anderson discusses an abstract from Journal of Clinical Oncology entitled Phase I Trial of…
Professor Galina Velikova, MD of the Leeds Institute of Medical Research discusses the ASCO abstract Phase III randomized controlled trial…
Jingxuan Zhao, MPH @AmercianCancer #ASCO20 Health insurance status and cancer stage at diagnosis and survival in the United States Bottom…
Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center discusses the Efficacy of Selpercatinib in RET-Altered…
Ben George, MD from Froedtert & Medical College discusses an ASCO 2020 abstract entitied A phase I, first-in-human, open-label, dose‑escalation,…
Jan Schellens, MD, CMO Byondis discusses the Phase I Study of Antibody-Drug Conjugate SYD1875. 11 August 2020, Nijmegen, The Netherlands,…
Nicolo Manaresi, Ph.D. Chief Scientific Officer of M Silicon Biosystems gives an overview of Two Studies Presented at AACR 20…
Allison Huegel, COO AxoProtego and Ahmet Hoke, MD, Ph.D. Johns Hopkins Medicine gives an overview of AxoProtego Therapeutics Announces Novel…
David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences discusses their Partners with Elevation Oncology…
Babar Bashir, MD from Jefferson Health discussed an ASCO 2020 abstract entitled BT5528-100 phase I/II study of the safety, pharmacokinetics,…
Patrick Glen Pilie, MD MD Anderson discusses an ASCO 2020 abstract entitled Identifying Functional Loss of ATM Gene In Patients…
Istvan Petak, MD #ASCO20 Oncompass Medicine SHIVA01 Trial Update Context: Precision oncology demands that individual molecular pathomechanisms be identified in…
Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS The optimisation of the…
Ignacio Garrido-Laguna, MD at Huntsman Cancer Institute discusses the ASCO 2020 abstract entitled A phase I, first-in-human, open-label, dose‑escalation, safety,…
Wilson H. Miller, MD Jewish General Hospital discusses an ASCO 2020 abstract entitled A phase Ib study of oral Chk1…
Filip Janku, MD at MD Anderson discusses an ASCO 2020 abstract entitled Phase I study of IM156, a novel potent…
Scott Tomlins, MD, Ph.D. Co-Founder, and Chief Scientific Officer – Strata discusses the Strata Oncology Partners with Elevation Oncology to…
Audrey Guth, Nanny Angel Network – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award…
Astrid Margossian, MD @SEngineMedicine discusses an ASCO 2020 poster entitled Predictive value of a CLIA-approved organoid based drug sensitivity test…
Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of…
Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
Mark Stroh, Ph.D. – CytomX Therapeutics discusses CX-2009 Abstract – a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from…
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Cristian Massacesi, MD, Senior Vice President, Head of…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Robert Epstein, MD – Epstein Health, LLC. – discusses Real-world burden of chemotherapy-induced myelosuppression: Results of a U.S. online survey…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with…
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Khalil Choucair, MD – The Kansas University School of Medicine discusses Liquid biopsy: A community-based oncology practice experience. #ASCO2020 https://meetinglibrary.asco.org/record/188007/abstract
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation…
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation…
Razelle Kurzrock, MD – UC San Diego Health discusses a Comprehensive analysis of HER2 status through genomic, transcription, and translation…
Andrea Enzinger, MD Dana-Farber Cancer Institute discusses US trends and racial/ethnic disparities in opioid access among patients with poor prognosis…
In this video from our Cancer Basics series, Narjust Duma, MD, Assistant Professor and Thoracic Oncologist with the University of…
This quick tutorial shows in detail how to create an account on OncologyTube.com and how to upload a video. The…
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth explains how oncologists are using RWE today.
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth provides examples of how real-world evidence (RWE) has impacted…
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth defines real-world evidence (RWE) and explains how it can…
 First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to…
Source: https://www.spreaker.com/user/cancergrace/narjust-duma-md-introduces-cancer-myths- GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our…
Roman Hajek, MD of University of Ostrava discusses MM patients remaining under represented in clinical trials based on standard laboratory…
Baiyan Wang, MD of Hospital of Xi’an Jiaotong University discusses the LEGEND-2 data.
Alexey Danilov, MD of @OHSUNews discusses pharmacologic inhibition of SUMO-activating enzyme (SAE) with TAK-981 augments interferon signaling and regulates t…
Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust answers the common questions asked about the safety and…
Alexander Cohen, MBBS of Guys’ and St. Thomas’ NHS Foundation Trust discusses the safety and effectiveness of apixaban, LMWH, and…
Joint FDA/ASH Led Initiative Highlights Importance of Using Patient Reported Outcomes and Biomarkers in Clinical Trials to Advance SCD Therapies The American Society…
At the Icahn School of Medicine at Mount Sinai, the Human Immune Monitoring Center (HIMC) will use state-of – the-art…
Analyses from the Phase III JAVELIN Renal 101 study support efficacy of BAVENCIO plus axitinib across multiple subgroups of patients…
Mohammad Jahanzeb, MD shares data presented at WCLC 2019 that he found interesting.
– Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late-Breaking…
Austin, Texas – September 16, 2019 – The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, today…
Dr. Mehool Patel dicusses how artificial intelligence makes an impact on decisions for both clinicians and patients alike. Background: Next…
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses Shout-Out: Very Grateful For Everything…Maybe Not All…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses Questions About Larotrectinib: Who Should Be Tested,…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses Larotrectinib Efficacy & Safety In Pediatric TRK…
Douglas S. Hawkins MD Of The University of Washington School of Medicine Discusses How To Identify Patients With An NTRK…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of…
GRACE – Global Resource for Advancing Cancer EducationPublished on Mar 26, 2019GRACE is excited to bring to you a new…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined…
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to…
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of “liquid biopsies”, serum-based testing for molecular…
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation,…
Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November…
Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond…
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to…
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired…
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences…
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation…
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among…
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a “next generation sequencing”…
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among…
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation…
Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients…
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also…
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved…
The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates…
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance…
There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discusses the…
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In…
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers…
Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted…
Dr. Jack West, Brendan Bietry, and Janet Freeman-Daily take questions from the audience about financial assistance, legal protections, and patient…
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how…
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC…
Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses Research & Development Philosophy At Janssen. At The 60th ASH…
Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses Skepticism Regarding MACRA. At The 60th ASH…
Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses Key Factors Contributing To Physician Burnout. At…
Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses The Role Of Advanced Practice Practitioners. At…
Chadi Nabhan, MD, MBA VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses What Is Being Done To Prevent Oncologist…
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in…
In this video, Dharmisha Chauhan, MPharm, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of her…
Healthcare technologies and apps are important in supporting patients in their care, and can greatly benefit them in their treatment…
Kelly Baillie, of the NHS Greater Glasgow & Clyde, Glasgow, UK, presents the key findings from the Cancer Medicines Outcome…
From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College…
A specialist workshop on non-medical prescribing was hosted at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, Birmingham, UK.…
The British Oncology Pharmacy Association (BOPA) has a number of exciting educational initiatives in the pipeline for 2019. BOPA committee…
Advanced therapy medicinal products (ATMPs) are a novel class of medicines offering treatment options for diseases that currently lack effective…
Substitutable Medical Apps, Reusable Technologies (SMART) apps have been developed to meet the need for responsiveness in healthcare IT. In…
Following the unfortunate IT failures at the Barts Health NHS Trust in 2017, which led to major issues in their…
Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic…
What is the current treatment landscape for plasma cell leukemia and extramedullary disease in multiple myeloma (MM)? We spoke to…
The results of clinical trials are open to interpretation and are dependent upon a vast array of factors, including cohort…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host…
By understanding the pathogenesis of chronic graft-versus-host disease (GvHD), treatments can be better targeted to improve patient outcomes. In this…
Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, discusses the previous management of chronic graft-versus-host disease…
Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Fermin Sanchez-Guijo,…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Abdul Hamid Bazarbachi,…
Here, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, outlines the collaborative approach taken by his institution,…
In this video, Khaled Ghanem, MD, from the American University of Beirut, Beirut, Lebanon, encourages the use of social media,…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Khaled Ghanem, MD,…
From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana…
In this video, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth McGovern Medical School, Houston, TX, delivers advice to…
In this video, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana University Simon Cancer Center, Indianapolis, IN, describes how identifying molecular…
The importance of the clinical pharmacy specialist is often understated. Here, Judith Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP, of UTHealth…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Judith Smith, PharmD, BCOP, CPHQ, FCCP,…
Fermin Sanchez-Guijo, MD, PhD, of Hospital ClÃnico Universitario de Salamanca, Salmanca, Spain, speaks to us about the role of mesenchymal…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Ernst Holler, MD,…
Anti-thymocyte globulin (ATG) is immunosuppressive antibody that has been around for >30 years, which is used to prevent graft-versus-host disease…
Speaking from the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Genovefa Papanicolaou,…
In this video, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal,…
Denis Claude Roy, MD, FRCP, of the University of Montreal, Montreal, Canada, is involved in developing a technique for eradicating…
In recent years, there has been a massive increase in the number of different immunotherapeutic agents that can be used…
Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa…
Edward L. Nelson, MD, UC Irvine Health talks about hoe RET Inhibitors May Be Approved this Year | Systems-Based Approach…
Edward L. Nelson, MD, UC Irvine Health talk about PI3-Kinase Inhibitors Do Not Work in Tumor Agnostic Way | Targeted…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel Wolff, MD,…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, held in Denver, CO, Jill Kolesar, PharmD, MS, BCPS, FCCP,…
Edward L. Nelson, MD, UC Irvine Health says to Enroll Patients in Umbrella or Basket Trials | PI3-kinase Did Not…
In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic…
With the increased use of next-generation sequencing (NGS) to identify mutations in patient’s own cancer cells, the off-label usage of…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ginah Nightingale, PharmD, BCOP, of Thomas…
Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, discusses why cognitive impairment as a result of chemotherapy is…
There is increasing evidence to suggest that chemotherapy contributes to changes in cognition. In this interview, Ginah Nightingale, PharmD, BCOP,…
Joseph Bubalo, PharmD, BCOP, BCPS, of Oregon Health and Science University Hospital, Portland, OR, speaking from the 2018 Hematology/Oncology Pharmacy…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Jeanne McCarthy-Kaiser, PharmD, BCOP, of the…
Edward L. Nelson, MD, UC Irvine Health explains Number of Molecular Targets Are Overwhelming Practitioners | Practitioners Must Know What…
Edward L. Nelson, MD, UC Irvine Health explains Whether to ReBiopsy a Tumor | Give Practitioners Understanding of Modalities at…
Edward L. Nelson, MD, UC Irvine Health explains Topics Covered in ASCO 2018 | Precision Medicine, Next-Gen Sequencing, Tumor Cells,…
John Gribben, of Barts Cancer Institute, London, UK, discusses making CAR T-cells happen in Europe. This video was recorded at…
HARMONY is Europe’s largest public-private partnership for big data in hematology. Here, Jesús MarÃa Hernández Rivas, HARMONY Alliance Project Coordinator,…
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients…
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in…
Precision, or personalized, medicine has often been regarded as the future of cancer treatment. In this interview, Howard Burris, MD,…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.
CAR T-cells represent an important step forward in the treatment of a variety of hematological malignancies. At the American Society…
Howard A. “Skip” Burris III, MD, FACP, FASCO, explains some of the new and exciting concepts in clinical trial design
Eunice Wang, MD, talks about The most exciting data coming out of the 2018 Annual Meeting
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how Watson is…
Howard A. “Skip” Burris III, MD, FACP, FASCO, talks about his goals for the 2019 Annual Meeting.
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, shares how data from…
Lisa Rometty, Vice President and General Manager, Oncology, Life Sciences, and Personal Health, IBM Watson Health, talks about how augmented…
The British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, had a record number of clinical experts in…
Could patients who remain MRD negative long-term whilst on maintenance treatment cease treatment? Here, Ola Landgren, MD, PhD, from Memorial…
Very soon, minimal residual disease (MRD) testing will become a routine part of clinical practice. Therefore, it is important that…
Newer treatments for hematological malignancies, including immunotherapies and cellular therapies, are more targeted than historical chemotherapies. This means that the…
The measurement and use of minimal residual disease (MRD) is an exciting development in the world of hematological oncology. So,…
Randall A. Oyer, MD, Dr. Oyer explains how ACCC is contributing to the work being done to address disparities in…
Mark Levis, MD, PhD, shares his thoughts on the most exciting clinical trial data coming out of the 2018 Annual…
Noa Biran, MD, shares her opinion on the most exciting clinical data presented at the 2018 Annual Meeting Annual Meeting.
Gareth Morgan, MD, PhD, FRCP, FRCPath, from the University of Arkansas for Medical Sciences, Little Rock, AR, gives a brief…
Allogenic stem cell transplants are the only curative therapy available for several hematological diseases; however, graft-versus-host disease (GvHD) is a…
Randall A. Oyer, MD, explains the immunotherapy data coming out of the Annual Meeting 2018 and the purpose of the…